The Center for Biosimilars® recaps the top stories for the week of June 17, 2019.
Hi, I’m Samantha DiGrande for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of June 17.
Number 5: During the 24th Congress of the European Hematology Association, researchers reported on findings from a phase 1 trial of Amgen’s proposed eculizumab biosimilar.
Number 4: At the European League Against Rheumatism’s Annual European Congress of Rheumatology, researchers said a biosimilar adalimumab has a “significant advantage” over the reference in terms of injection pain.
Number 3: Irish hospitals will be offered an incentive for each patient switched from brand-name Humira or Enbrel to a biosimilar option.
Number 2: A new study has found that switching among multiple biosimilar infliximab products was not associated with increased immunogenicity.
Number 1: A Canadian advisory council is recommending the use of biosimilars in a final report that lays out recommendations for how the country can create a single-payer public system for pharmaceutical coverage.
Finally, last week, our e-newsletter asked whether you think that anticancer biosimilars will have swifter US uptake than biosimilars that treat inflammatory diseases.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.